372 related articles for article (PubMed ID: 28623843)
1. Proposal for long-term protocols after Psoriasis Area and Severity Index clear with initial biologic therapy: Happily ever after with or without biologics in psoriasis therapy.
Sano S
J Dermatol; 2017 Oct; 44(10):e234-e235. PubMed ID: 28623843
[No Abstract] [Full Text] [Related]
2. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
3. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
[TBL] [Abstract][Full Text] [Related]
4. Review of safety and efficacy of approved systemic psoriasis therapies.
Kaushik SB; Lebwohl MG
Int J Dermatol; 2019 Jun; 58(6):649-658. PubMed ID: 30246393
[TBL] [Abstract][Full Text] [Related]
5. Geographic Variations in Biologic Therapy and Disease Characteristics: A Pilot-Study in the Corrona Psoriasis Registry.
Enos CW; O'Connell KA; Harrison RW; McLean RR; Dude B; Van Voorhees AS
J Drugs Dermatol; 2020 Nov; 19(11):1119-1122. PubMed ID: 33196741
[No Abstract] [Full Text] [Related]
6. Comparative efficacy of topical antipsoriatic treatments, systemic treatment and biologics: is severity assessment beyond Psoriasis Area and Severity Index a necessity?
van de Kerkhof PC; Mrowietz U; Segaert S; Kragballe K
Br J Dermatol; 2007 Apr; 156(4):771-2. PubMed ID: 17263798
[No Abstract] [Full Text] [Related]
7. Serum fatty acid-binding protein 4 level is inversely correlated with serum thymus and activation-regulated chemokine level in psoriatic patients achieving clear skin by biologics.
Honma M; Shibuya T; Iinuma S; Ishida-Yamamoto A
J Dermatol; 2019 Apr; 46(4):e116-e117. PubMed ID: 30216494
[No Abstract] [Full Text] [Related]
8. Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study.
Qiang JK; Shahbaz A; Kim W; Marinas J; Greaves S; Yeung J
J Am Acad Dermatol; 2016 Jan; 74(1):176-7. PubMed ID: 26702799
[No Abstract] [Full Text] [Related]
9. Practical experience of biologics for treatment of very severe psoriasis: a retrospective case cohort study of patients with a baseline Psoriasis Area and Severity Index greater than 20.
Ponnambath N; Kalavala M; Anstey AV; Piguet V; Ingram JR
Clin Exp Dermatol; 2016 Jan; 41(1):95-6. PubMed ID: 25817265
[No Abstract] [Full Text] [Related]
10. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
Alwawi EA; Krulig E; Gordon KB
Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
[TBL] [Abstract][Full Text] [Related]
11. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM).
Sbidian E; Mezzarobba M; Weill A; Coste J; Rudant J
Br J Dermatol; 2019 Jan; 180(1):86-93. PubMed ID: 29791721
[TBL] [Abstract][Full Text] [Related]
12. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
13. Treating to Target-A Realistic Goal in Psoriasis?
Gordon KB; Armstrong AW; Menter MA; Wu JJ
Semin Cutan Med Surg; 2018 Feb; 37(2S):S44-S47. PubMed ID: 29614137
[TBL] [Abstract][Full Text] [Related]
14. Switching of biologics in psoriasis: Reasons and results.
Honda H; Umezawa Y; Kikuchi S; Yanaba K; Fukuchi O; Ito T; Nobeyama Y; Asahina A; Nakagawa H
J Dermatol; 2017 Sep; 44(9):1015-1019. PubMed ID: 28488283
[TBL] [Abstract][Full Text] [Related]
15. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed.
Kimmel G; Chima M; Kim HJ; Bares J; Yao CJ; Singer G; Kim SJ; Bagel J; Lebwohl M
J Am Acad Dermatol; 2019 Sep; 81(3):857-859. PubMed ID: 31078609
[No Abstract] [Full Text] [Related]
16. From conventional to cutting edge: the new era of biologics in treatment of psoriasis.
Tzu J; Kerdel F
Dermatol Ther; 2008; 21(2):131-41. PubMed ID: 18394087
[TBL] [Abstract][Full Text] [Related]
17. The role of biologics and other systemic agents in the treatment of pediatric psoriasis.
Wright NA; Piggott CD; Eichenfield LF
Semin Cutan Med Surg; 2010 Mar; 29(1):20-7. PubMed ID: 20430304
[No Abstract] [Full Text] [Related]
18. Biologic treatments for elderly patients with psoriasis.
Momose M; Asahina A; Hayashi M; Yanaba K; Umezawa Y; Nakagawa H
J Dermatol; 2017 Sep; 44(9):1020-1023. PubMed ID: 28439956
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of systemic treatments for psoriasis in elderly patients.
Piaserico S; Conti A; Lo Console F; De Simone C; Prestinari F; Mazzotta A; Gualdi G; Guarneri C; Borsari S; Cassano N
Acta Derm Venereol; 2014 May; 94(3):293-7. PubMed ID: 24158307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
